Modification Of Viruses (e.g., Attenuation, Etc.) Patents (Class 435/173.3)
  • Patent number: 11260090
    Abstract: Provided are modified arenaviruses and populations thereof, wherein the modified arenaviruses include i) an introduced PPXY domain; ii) an increased number of PPXY domains; iii) a substituted amino acid in place of S41 in a viral Z protein that is not a substrate for a serine or tyrosine kinase, or a combination of i)-iii). A PPXY domain can include a phosphomimetic replacement of the Y amino acid. Modified Old World and New World arenaviruses are included. Arenavirus production is provided using cell cultures that contain a kinase inhibitor that inhibits a kinase that can phosphorylate the Y amino acid of the PPXY domain, or by cells that have disrupted kinase gene expression, or by cells that have a disrupted ESCRT system. Also provided are pharmaceutical formulations that contain modified arenaviruses, and methods of using such formulations for stimulating an immune response hat is fully or partially protective against arenavirus infection.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: March 1, 2022
    Assignee: University of Vermont and State Agricultural College
    Inventors: Emily Adaline Bruce, Jason William Botten, Christopher Michael Ziegler
  • Patent number: 10624935
    Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: April 21, 2020
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Barbara Leuchs, Karsten Geletneky, Jean Rommelaere, Christiane Dinsart, Michael Dahm, Ottheinz Krebs
  • Patent number: 10463723
    Abstract: Provided herein are methods for generating dry vaccine powder formulations. Dry vaccine powder formulations can be used for intranasal delivery. Also provided are methods for stimulating local mucosal and systemic immunity by intranasal vaccine delivery.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 5, 2019
    Assignee: Shin Nippon Biomedical Laboratories, Ltd.
    Inventors: Ryoichi Nagata, Shunji Haruta
  • Patent number: 9234168
    Abstract: The invention provides methods of producing vaccines directed against microorganisms, with the methods comprising culturing, harvesting and/or suspending the microorganism in the presence of a radiation-protective composition and irradiating the bacteria or viruses with a dose of radiation sufficient to render the microorganism replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide. The invention also provides methods of rendering bacteria in culture resistant to ionizing radiation (IR), with these methods comprising culturing the bacteria in the presence of a radiation-protective composition.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: January 12, 2016
    Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
    Inventors: Michael J. Daly, Elena K. Gaidamakova
  • Publication number: 20140314810
    Abstract: The invention provides methods of producing vaccines directed against methicillin-resistant Staphylococcus aureus (MRSA) or Venezuelan equine encephalitis virus (VEEV), with the methods comprising culturing, harvesting and/or suspending the MRSA or VEEV in the presence of a radiation-protective composition and irradiating the MRSA with a dose of radiation sufficient to render the MRSA or VEEV replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide.
    Type: Application
    Filed: November 1, 2012
    Publication date: October 23, 2014
    Applicant: United States Department of Health and Human Services
    Inventors: Michael Daly, Elena K Gaidamakova, Ian A. Myles, Patricia A. Valdez, Sandip K. Datta
  • Patent number: 8679736
    Abstract: The methods of this invention involve preventing the formation of a complex between adenine and riboflavin by reducing the amount of adenine in a solution containing blood or blood components to be pathogen reduced.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: March 25, 2014
    Assignee: Terumo BCT Biotechnologies, LLC
    Inventors: Raymond P. Goodrich, Suzann K. Doane
  • Patent number: 8613934
    Abstract: The invention involves inactivation of viral populations by treating the viral populations with a compound to crosslink proteins in the viral membrane, UV irradiation and further inactivation of the viruses using detergent(s). According to the invention, this method preserves the native structure of viral epitopes so that the inactivated viral preparations can be used in immunological compositions that will inhibit and/or prevent viral infection when administered to an animal.
    Type: Grant
    Filed: July 30, 2010
    Date of Patent: December 24, 2013
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Yossef Raviv, Julie M. Belanger, Mathias Viard, Robert Blumenthal, Julian W. Bess, Jr.
  • Publication number: 20130209508
    Abstract: The invention provides methods of producing vaccines directed against microorganisms, with the methods comprising culturing, harvesting and/or suspending the microorganism in the presence of a radiation-protective composition and irradiating the bacteria or viruses with a dose of radiation sufficient to render the microorganism replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide. The invention also provides methods of rendering bacteria in culture resistant to ionizing radiation (IR), with these methods comprising culturing the bacteria in the presence of a radiation-protective composition.
    Type: Application
    Filed: April 29, 2011
    Publication date: August 15, 2013
    Inventors: Michael J. Daly, Elena K. Gaidamakova
  • Publication number: 20130078702
    Abstract: An apparatus (100) capable of viral inactivation of liquid media includes at least one coaxial cylinder (110) constructed of an outer cylinder (120) and an inner cylinder (130), a liquid media inlet (140), at least one emitter of type C ultraviolet radiation (145), and a liquid media outlet (150). The inner cylinder has an outer diameter adapted to form a gap (160) between the outer diameter of the inner cylinder and the inner diameter of the outer cylinder. The media flows in a substantially cyclonic flow path along the gap. The at least one emitter of type C ultraviolet radiation is placed inside the inner cylinder. The outlet is connected to the outer cylinder at, or proximal to, an end of the outer cylinder opposite the inlet.
    Type: Application
    Filed: June 6, 2011
    Publication date: March 28, 2013
    Applicant: GENZYME CORPORATION
    Inventor: Muthukumar Dhanasekharan
  • Publication number: 20130045230
    Abstract: The present invention is related to a composition comprising an agent selected from the group comprising HCMV virions, HCMV dense bodies and HCMV NIEP, whereby the composition is capable of elucidating an immune response while the virions, the NIEP and/or the dense bodies being non-fusiogenic.
    Type: Application
    Filed: September 13, 2012
    Publication date: February 21, 2013
    Applicants: RHEIN BIOTECH GMBH, VAKZINE PROJEKT MANAGEMENT GMBH
    Inventor: Leander GRODE
  • Publication number: 20130004534
    Abstract: Azido-diarylpyrimidine (azido-DAPY) compounds, and compositions containing such compounds, are provided. In addition, methods of using azido-diarylpyrimidines to inactivate reverse transcriptases, prepare inactivated viruses, and treat or prevent viral infections are also provided.
    Type: Application
    Filed: September 11, 2012
    Publication date: January 3, 2013
    Inventor: Adan Rios
  • Publication number: 20120270292
    Abstract: The present disclosure relates generally to systems and methods for the photo-inactivation of microorganisms. More specifically, the present invention is directed towards the photo-inactivation of microorganisms, such as viruses, using at least one furanocoumarin and broad spectrum pulsed light. For example, an aspect of the present invention includes a method for inactivating a herpesvirus, such as herpes B virus or herpes virus papio 2 using a psoralen and broad spectrum pulsed light.
    Type: Application
    Filed: December 20, 2010
    Publication date: October 25, 2012
    Applicant: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Julia Hilliard, David Katz
  • Patent number: 8278083
    Abstract: The invention provides compositions of inactivated influenza virus that can be used as vaccines and immunological compositions useful for inhibiting, preventing and treating influenza.
    Type: Grant
    Filed: March 23, 2007
    Date of Patent: October 2, 2012
    Assignees: The United States of America as represented by the Secretary of the Department of Health and Human Services, University of Georgia Research Foundation, Inc.
    Inventors: Yossef Raviv, Mathias Viard, Robert Blumenthal, Robert J. Hogan, Stephen Mark Tompkins
  • Patent number: 8268602
    Abstract: The invention provides compositions of inactivated viruses, bacteria, fungi, parasites and tumor cells that can be used as vaccines. Methods for making such inactivated viruses, bacteria, fungi, parasites and tumor cells are also provided.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: September 18, 2012
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Yossef Raviv, Mathias Viard, Robert Blumenthal
  • Patent number: 8125333
    Abstract: The present disclosure provides for methods, systems and apparatus for monochromatic UV light sterilization of container systems and/or container-packaged products. More particularly, the present disclosure provides for improved methods, systems and apparatus for monochromatic UV light sterilization of liquid and/or solid products/solutions and/or packaging/container systems for liquid and/or solid products/solutions (e.g., parenteral pharmaceutical products/solutions and/or packaging/container systems for parenteral pharmaceutical products/solutions).
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: February 28, 2012
    Assignee: Triton Thalassic Technologies, Inc.
    Inventors: Barry Ressler, Bernard Anthony McNulty
  • Publication number: 20120046593
    Abstract: Provided herein are methods and systems to increase selective thermomechanical damage to a biological body, such as a cancer cell or cell associated with a pathophysiological condition. The biological body or cancer cell is specifically targeted with nanoparticulates comprising one or more targeting moieties which form nanoparticulate clusters thereon or therewithin. Pulsed electromagnetic radiation, e.g., optical radiation, having a wavelength spectrum selected for a peak wavelength near to or matching a peak absorption wavelength of the nanoparticulates selectively heats the nanoparticulates thereby generating vapor microbubbles around the clusters causing damage to the targets without affecting any surrounding medium or normal cells or tissues. Also provided are methods for treating leukemia and for selectively and thermomechanically causing damage to cells associated with a pathophysiological condition using the methods and system described herein.
    Type: Application
    Filed: August 15, 2011
    Publication date: February 23, 2012
    Inventors: Alexander Oraevsky, Dmitri Lapotko
  • Publication number: 20120034267
    Abstract: The invention provides an inactivated varicella zoster virus (VZV), and compositions and vaccines comprising said inactivated VZV, wherein the infectivity of the VZV is undetectable and wherein the inactivated VZV induces an immune response against VZV when administered to a patient. In embodiments of the compositions described herein, the VZV is inactivated with gamma radiation. The invention also provides a method of preparing an inactivated VZV vaccine, the method comprising gamma irradiating a sample comprising a VZV using from about 5 kGy to about 50 kGy of gamma radiation. Also provided by the invention herein is a method of treatment of or immunization against HZ or other disease associated with the reactivation of VZV, the method comprising administering to a subject a vaccine or pharmaceutical composition comprising a therapeutically effective amount of an inactivated VZV and a pharmaceutically acceptable carrier, wherein the VZV is inactivated by gamma irradiation.
    Type: Application
    Filed: August 4, 2011
    Publication date: February 9, 2012
    Inventors: David L. Krah, Jill DeHaven, Jennifer A. Kriss, Colleen M. Barr, Mary Yagodich
  • Publication number: 20110143414
    Abstract: A microfluidic device for the concentration and lysis of cells or viruses and a method of concentrating and lysing cells or viruses using the microfluidic device include: magnetic beads, a reaction chamber in which the magnetic beads are accommodated and a laser source. The reaction chamber includes a plurality of electrodes which cross each other and are separated by a dielectric to generate an electric field and a vibrating part agitating the magnetic beads in the chamber. The laser source radiates a laser onto the magnetic beads in the reaction chamber.
    Type: Application
    Filed: February 25, 2011
    Publication date: June 16, 2011
    Applicant: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Yoon-kyoung CHO, Jeong-gun LEE, Sung-young JEONG
  • Patent number: 7939085
    Abstract: The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: May 10, 2011
    Assignee: Bavarian Nordic A/S
    Inventors: Anton Mayr, Barbara Mayr
  • Publication number: 20110076735
    Abstract: Methods and devices for the interfacing of microchips to various types of modules are disclosed. The technology disclosed can be used as sample preparation and analysis systems for various applications, such as DNA sequencing and genotyping, proteomics, pathogen detection, diagnostics and biodefense.
    Type: Application
    Filed: June 15, 2010
    Publication date: March 31, 2011
    Inventors: Stevan B. Jovanovich, Iuliu I. Blaga
  • Publication number: 20110038890
    Abstract: The invention involves inactivation of viral populations by treating the viral populations with a compound to crosslink proteins in the viral membrane, UV irradiation and further inactivation of the viruses using detergent(s). According to the invention, this method preserves the native structure of viral epitopes so that the inactivated viral preparations can be used in immunological compositions that will inhibit and/or prevent viral infection when administered to an animal.
    Type: Application
    Filed: July 30, 2010
    Publication date: February 17, 2011
    Inventors: Yossef Raviv, Julie M. Belanger, Mathias Viard, Robert Blumenthal, Julian W. Bess, JR.
  • Publication number: 20110020893
    Abstract: The invention describes a way to target and trap a specific particle (atom, molecule, bacterium, photon, ion, virus, etc.) that can be extracted from a moving fluid flow. Since every particle has a unique and identifiable shape and/or electromagnetic signature, a trap can be built to target it. The fluid is assumed to be moving and the trap is to be placed in the flow to capture the specific particle. Other particles would not be captured unless specifically targeted. Once trapped, the particle can be returned to the flow or be pulled out, the trap cleaned and replaced to catch a new particle. This can be used to remove specific particles from the fluid flow for mining purposes or to clean the fluid (EG. removing sodium molecules from flowing water or removing a virus from the blood stream).
    Type: Application
    Filed: July 27, 2009
    Publication date: January 27, 2011
    Inventor: Andrew Bransford Brown
  • Publication number: 20110008387
    Abstract: The present invention is related to a composition comprising an agent selected from the group comprising HCMV virions, HCMV dense bodies and HCMV NIEP, whereby the composition is capable of elucidating an immune response while the virions, the NIEP and/or the dense bodies being non-fusiogenic.
    Type: Application
    Filed: May 13, 2008
    Publication date: January 13, 2011
    Inventor: Leander Grode
  • Patent number: 7648699
    Abstract: This invention is directed toward a process for reducing transfusion related complications in a recipient of an allogeneic blood transfusion by adding to the blood to be transfused a photosensitizer comprising riboflavin, irradiating the blood and riboflavin with light, transfusing the irradiated blood into a recipient, and reducing a transfusion related complication by the recipient to cells in the donor blood. The invention is also directed towards a process for preventing rejection of a donor organ by a recipient comprising the steps of transfusing the recipient of the donor organ with treated platelets; and transplanting the donor organ into the recipient.
    Type: Grant
    Filed: August 31, 2006
    Date of Patent: January 19, 2010
    Assignee: CaridianBCT Biotechnologies, LLC
    Inventors: Raymond P. Goodrich, Junzhi Li
  • Publication number: 20090297558
    Abstract: The invention provides compositions of inactivated influenza virus that can be used as vaccines and immunological compositions useful for inhibiting, preventing and treating influenza.
    Type: Application
    Filed: March 23, 2007
    Publication date: December 3, 2009
    Inventors: Yossef Raviv, Mathias Viard, Robert Blumenthal, Robert J. Hogan, Stephen Mark Tompkins
  • Patent number: 7560527
    Abstract: The invention concerns an adenovirus fiber modified by mutation of one or several residues of the region included between residues 491 and 505 of SEQ ID NO: 1, the viral particles or pseudo-particles comprising such a fiber and their uses.
    Type: Grant
    Filed: November 23, 2000
    Date of Patent: July 14, 2009
    Assignee: Transgene S.A.
    Inventors: Valérie Legrand, Philippe Leissner
  • Publication number: 20080177359
    Abstract: The present invention relates to the process of selectively exposing matter to a specific wavelength of electromagnetic energy in sufficient flux density per wavelength to cause or promote a desired effect. The process includes, but is not limited to, destroying, disinfecting, denaturing, disinfesting, disrupting, or dehydration of one or more of the substances present. More specifically, present invention relates to subjecting matter, which may contain a mixture of substances, to electromagnetic energy, in concurrence with its spectral properties to exploit the spectral differences within the substance or within a mixture of substances. Energies are applied to cause wavelength-dependent reactions resulting from differential absorption; this additional applied energy manifests itself in changes, or quantum transitions, in the vibrational, rotational, magnetic, and electronic states of the molecules.
    Type: Application
    Filed: March 27, 2008
    Publication date: July 24, 2008
    Applicant: Advanced Light Technology, LLC.
    Inventor: Brian N. Pierce
  • Patent number: 7282358
    Abstract: Methods, systems and apparatus for photo-processing of fluids, particularly complex fluids, such as blood products, pharmaceuticals, injectables and vaccines, are provided. The disclosed methods and systems employ non-laser light source(s) to generate monochromatic light energy, preferably in the range of 260 nm to 310 nm, for fluid treatment. Advantageous processing regimens and/or adjunct additives and/or agents may also be used to achieve desired and/or enhanced results, e.g., inactivation of pathogens, bacteria and/or viruses, modulation of immune response, and/or leukoreduction. Particularly preferred embodiments include specific wavelengths, novel temperature control systems and geometric/structural arrangements that provide enhanced processing results and/or efficiencies.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: October 16, 2007
    Assignee: Triton Thalassic Technologies, Inc.
    Inventors: John Coogan, Barry Ressler
  • Patent number: 7132277
    Abstract: The present invention features helper-dependent adenoviral vector elements, and helper adenoviral elements, that enhance the production and isolation of helper-dependent adenoviral vectors. Such elements include a modified packaging signal having low homology to, and preferably less activity than, a wild-type packaging signal, an E4 non-coding segment directly joined to the 5? ITR that confers a selective advantage, and stuffer region(s) that provide a helper-dependent adenoviral vector with a GC content of about 50% to about 60%. The modified packaging signal is preferably used in a helper virus to decrease recombination and generation of the virus. The E4 non-coding segment and the stuffer region(s) are preferably used in a helper-dependent adenoviral vector to provide the vector with a growth advantage over a helper virus.
    Type: Grant
    Filed: January 31, 2000
    Date of Patent: November 7, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Andrew Bett, Volker Sandig, Rima Youil
  • Patent number: 7049110
    Abstract: Methods and apparatuses are provided for inactivation of microorganisms in fluids or on surfaces. Preferably the fluids contain blood or blood products and comprise biologically active proteins. Preferred methods include the steps of adding an effective, non-toxic amount of a photosensitizer to a fluid and exposing the fluid to photoradiation sufficient to activate the photosensitizer whereby microorganisms are inactivated.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: May 23, 2006
    Assignee: Gambro, Inc.
    Inventors: Heather Reddy, Raymond P. Goodrich
  • Patent number: 7045344
    Abstract: In vitro methods for making a recombinant adenoviral genome, as well as kits for practicing the same and the recombinant adenovirus vectors produced thereby, are provided. In the subject methods, the subject genomes are prepared from first and second vectors. The first vector includes an adenoviral genome having an E region deletion and three different, non-adenoviral restriction endonuclease sites located in the E region. The second vector is a shuttle vector and includes an insertion nucleic acid flanked by two of the three different non-adenoviral endonuclease sites present in the first vector. Cleavage products are prepared from the first and second vectors using the appropriate restriction endonucleases. The resultant cleavage products are then ligated to produce the subject recombinant adenovirus genome. The subject adenoviral genomes find use in a variety of applications, including as vectors for use in a variety of applications, including gene therapy.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: May 16, 2006
    Assignees: The Board of Trustees of the LeLand Stanford Junior University, The University of Washington
    Inventors: Mark A. Kay, Hiroyuki Mizuguchi
  • Patent number: 7041441
    Abstract: Disclosed is a phage display system in which the molecules to be displayed (i.e., molecules of interest) are bound to dispensable capsid polypeptides such as SOC (small outer capsid) and HOC (highly antigenic outer capsid) polypeptides that are, in turn, bound to a surface lattice protein, such as those on the surface of a virion or polyhead. Also disclosed are methods of displaying a molecule of interest, methods of immunizing a patient by administering a displayed antigen, and methods of treating a patient who has a disorder associated with aberrent expression or activity of a biological molecule. In the latter instance, the method includes administering a displayed polypeptide, such as an immunoglobulin molecule or an enzyme, that is capable of specifically interacting with the aberrent biological molecule.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: May 9, 2006
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Alasdair C. Steven, Paul T. Wingfield, Lindsay W. Black, Zhaojun Ren
  • Patent number: 7018826
    Abstract: The present invention relates to particles, comprising: a protein envelope with a fusion protein, which comprises a virus protein, a cell permeability-mediating peptide and a heterologous cell-specific binding site; and a nucleic acid present in the protein envelope, which comprises the sequence for a virus-specific packaging signal and a structural gene. The invention further relates to methods for the preparation of such particles and means suitable for this purpose, as well as the use of the particles in gene therapy.
    Type: Grant
    Filed: February 4, 2000
    Date of Patent: March 28, 2006
    Assignee: Island Pharmaceuticals Ltd.
    Inventors: Eberhard Hildt, Peter Hofschneider
  • Patent number: 6967076
    Abstract: Recombinant expression vectors and methods are provided for detecting HIV and monitoring HIV drug resistance.
    Type: Grant
    Filed: March 29, 2002
    Date of Patent: November 22, 2005
    Assignee: MUSC Foundation for Research Development
    Inventor: Jian-yun Dong
  • Patent number: 6951754
    Abstract: The present invention is based on the development of a dual promoter system (preferably a RNA pol I-pol II system) for the efficient intracellular synthesis of viral RNA. The resultant minimal plasmid-based system may be used to synthesize any RNA virus, preferably viruses with a negative single stranded RNA genome. The viral product of the system is produced when the plasmids of the system are introduced into a suitable host cell. One application of the system is production of attenuated, reassortant influenza viruses for use as antigens in vaccines. The reassortant viruses generated by cotransfection of plasmids may comprise genes encoding the surface glycoproteins hemagglutinin and neuramimidase from an influenza virus currently infecting the population and the internal genes from an attenuated influenza virus. An advantageous property of the present invention is its versatility; the system may be quickly and easily adapted to synthesize an attenuated version of any RNA virus.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: October 4, 2005
    Assignee: St. Jude Children's Research Hospital
    Inventor: Erich Hoffmann
  • Patent number: 6884422
    Abstract: The present invention relates to hepatitis A vaccine, especially to a lyophilized attenuated hepatitis A vaccine which can be stored at ambient temperature for extended periods of time, and to a method for producing the same. The present invention further relates to a stabilizer for lyophilized live vaccine and its use in improving thermostability of lyophilized live vaccine during lyophilization processing and storage period after lyophilization.
    Type: Grant
    Filed: October 10, 1999
    Date of Patent: April 26, 2005
    Assignee: Changchun Institute of Biological Products, Ministry of Public Health
    Inventors: Jingye Liu, Pengfu Wang, Guangpu Li, Baosheng Xie, Zongming Song, Shuyan Li, Jing Liu, Ying Yu, Xizhen Guangpu Zhang, Ben Liang, Lingjiu Liu, Wei Wang, Ling Zhang, Yong Xue, Jing Li, Yuhong Li, Hui Lin, Zongju Wan
  • Patent number: 6872576
    Abstract: The invention relates to an immunoassays, binding assays, solid phase substrates (12) and other devices with an antigen or antibody or ligand or receptor (11) embedded into a solid phase substrate (12). The antigen or antibody is mixed with a molten thermoplastic and formed into the solid phase substrate (12).
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: March 29, 2005
    Assignee: Embedded Concepts, LLC
    Inventor: John A. McIntyre
  • Patent number: 6849446
    Abstract: The present invention provides modified bovine adenoviruses comprising a modification in a capsid protein wherein said protein is associated with adenovirus tropism and wherein said modification is associated with altered tropism. The present invention provides adenovirus vectors and host cells comprising such vectors. The present invention also provides methods of making and using such adenoviruses.
    Type: Grant
    Filed: May 31, 2001
    Date of Patent: February 1, 2005
    Assignee: University of Saskatchewan
    Inventors: Suresh K. Tikoo, Lorne A. Babiuk, Linong Zhang, Qiaohua Wu
  • Patent number: 6803041
    Abstract: A vaccine for protecting a horse against diseases associated with EHV-1 and/or EHV-4 is provided. The vaccine commonly includes inactivated EHV-1 (e.g., chemically inactivated EHV-1 KyA virus) and an adjuvant. The adjuvant can include a cross-linked olefinically unsaturated carboxylic acid polymer which may have bioadhesive properties. The vaccine may also include antigens against other equine pathogens such as inactivated EHV-4 and inactivated A1 and/or A2 strains of equine influenza virus. Methods for protecting horses against diseases associated with EHV-1 and/or EHV-4 and methods of producing the equine herpesvirus vaccine are also provided.
    Type: Grant
    Filed: March 20, 2001
    Date of Patent: October 12, 2004
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventor: Mark W. Mellencamp
  • Patent number: 6794404
    Abstract: A compound of the formula I: wherein: X is CH or N; Y is O or S; Z is OH, NH2, NMeR3, NHR3; OR3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from O, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR7 or CR5, wherein R5 is H, halogen, or (C1-6) alkyl and R7 is H or (C1-6 alkyl), with the proviso that X and A are not both N; R6 is H, halogen, (C1-6 alkyl) or OR7, wherein R7 is H or (C1-6 alkyl); R1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C1-3)alkyl, (C2-6)alkenyl, phenyl(C2-6)alkenyl, (C3-6)cycloalkyl, (C1-6)alkyl, CF3, 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C2-6)alkenyl and phenyl(C1-3)alkyl), alkenyl, cycloalkyl, (C1-6)alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents; R2 is selected from (C1-6)alkyl, (C
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: September 21, 2004
    Assignee: Boehringer Ingelheim (Canada) Ltd.
    Inventors: Pierre Louis Beaulieu, Gulrez Fazal, James Gillard, George Kukolj, Volkhard Austel
  • Patent number: 6740511
    Abstract: The present invention relates to a modified fiber of an adenovirus, comprising at least one mutation at one or more residues within the region of said fiber stretching from pleated sheet A to pleated sheet B, and including loop AB.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: May 25, 2004
    Assignees: Transgene S.A., European Molecular Biology Laboratory (EMBL)
    Inventors: Mark Johan Van Raaij, Stephen Cusack, Valérie Legrand, Philippe Leissner, Majid Mehtali
  • Patent number: 6733757
    Abstract: Polypeptides of adeno-associated virus (AAV) that bind to AAV antibodies or block binding of AAV to mammalian cells are described. Derivatives of peptides can be less immunogenic, enhance binding to cells, render a virus tissue specific and so on. The nucleic acid sequence encoding those derivatives can be incorporated into a capsid encoding sequence to enable a virus to express such a derivative and be less immunogenic, have enhanced transduction efficiency or be tissue specific.
    Type: Grant
    Filed: November 14, 2002
    Date of Patent: May 11, 2004
    Inventors: Salil D. Patel, James G. McArthur
  • Patent number: 6730305
    Abstract: The present invention relates to recombinant DNA molecules which encode bovine respiratory syncytial (BRS) virus proteins, to BRS virus proteins, and peptides and to recombinant BRS virus vaccines produced therefrom. It is based, in part, on the cloning of substantially full length cDNAs which encode the entire BRS virus G, F, and N proteins. According to particular embodiments of the invention, DNA encoding a BRS virus protein or peptide may be used to diagnose BRS virus infection, or, alternatively, may be inserted into an expression vector, including, but not limited to, vaccinia virus as well as bacterial, yeast, insect, or other vertebrate vectors. These expression vectors may be utilized to produce the BRS virus protein or peptide in quantity; the resulting substantially pure viral peptide or protein may be incorporated into subunit vaccine formulations or may be used to generate monoclonal or polyclonal antibodies which may be utilized in diagnosis of BRS virus infection or passive immunization.
    Type: Grant
    Filed: May 8, 2000
    Date of Patent: May 4, 2004
    Assignee: The UAB Research Foundation
    Inventors: Gail W. Wertz, Robert Lerch
  • Patent number: 6730923
    Abstract: An apparatus for carrying a target object having a plurality of surfaces, within a pulsed light sterilization chamber including a treatment zone within which pulsed sterilizing light is emitted, comprises: a transmissive carrier within the treatment zone detachably coupled to the target object, the transmissive carrier having a transmissivity of at least about 10% to light within the 250 to 350 nm wavelength range; and moving means coupled to the transmissive carrier for moving the target object on the transmissive carrier through the treatment zone, the plurality of surfaces of the target object being sterilized by the pulsed sterilizing light in the treatment zone.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: May 4, 2004
    Assignee: PurePulse Technologies, Inc.
    Inventors: Richard May, Andrew H. Bushnell, William Fries
  • Patent number: 6719981
    Abstract: The present invention relates to recombinant rabies virus mutants comprising a mutation in the viral genome, whereby said mutation comprises at least a substitution of the Arg333 codon in the gene encoding the G protein with a codon that differs by three nucleotides from said Arg333 codon. These rabies virus mutants have a glycoprotein G that comprises an amino acid at position 333 which is encoded by a codon that differs by all three nucleotides from the Arg codon in amino acid position 333 in the glycoprotein of the parental virus. Said recombinant rabies virus mutants are stable and non-pathogenic in immune competent animals and are suitable for use in a live, attenuated anti-rabis vaccine.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: April 13, 2004
    Assignee: Akzo Nobel N.V.
    Inventors: Teshome T Mebatsion, Karl Klaus Conzelmann
  • Patent number: 6682883
    Abstract: The invention provides methods and kits for use in diagnosing flavivirus infection.
    Type: Grant
    Filed: July 19, 2001
    Date of Patent: January 27, 2004
    Assignee: Acambis, Inc.
    Inventors: Thomas P. Monath, Richard D. Nichols, Jr.
  • Patent number: 6569422
    Abstract: The present invention relates to a method for the adaptation of infectious bursal disease viruses (IBDV) to growth in CEF cell culture. Changing the codons for amino acid residues 253 (Gln) and 284 (Ala) to 253 (His) and 284 (Thr) allowed bursa adapted Classical and Variant-E IBDV to grow in CEF cell culture. For GLS IBDV only a change of the codon for amino acid residue 284 was necessary.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: May 27, 2003
    Assignee: Akzo Nobel N.V.
    Inventors: Adriaan Antonius Wilhelmus Maria van Loon, Egbert Mundt
  • Publication number: 20030092145
    Abstract: A composition for treating or preventing virus-induced infections is described, along with a process of producing the composition and methods of the composition's use. The composition comprises viral pathogen-infected cell or tissue, or malignantly or immunologically aberrant cells or tissues which has been reduced and/or denatured. The preferred composition is administered across a mucosal surface of an animal suffering or about suffer from infection. The composition is administered as preventive or therapeutic vaccine.
    Type: Application
    Filed: August 23, 2001
    Publication date: May 15, 2003
    Inventors: Vic Jira, Vichai Jirathitikal
  • Patent number: 6562350
    Abstract: A combined hepatitis A-measles live vaccine, its lyophilized formulations with enhanced storage stability and methods of preparing the same by mixing the viral stocks of hepatitis A virus and measles virus or by propagating the two viruses on same diploid cell substrate are disclosed. The combined live vaccine thus prepared is a useful vaccine for preventing the infections with hepatitis A and measles without causing any interference between antigenicity of the two viruses and any serious adverse events due to their mixing or co-culturing.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: May 13, 2003
    Assignee: Changchun Institute of Biological Products, Ministry of Public Health
    Inventors: Pengfu Wang, Jingye Lu, Guangpu Li, Baosheng Xie, Zongming Song, Shuyan Li
  • Patent number: 6562599
    Abstract: A DNA characterized by coding for a single-stranded antibody capable of binding to a hepatitis B virus core protein: a single-stranded antibody coding for the DNA: a therapeutic agent for hepatitis B comprising the single-stranded antibody as the active ingredient; and a gene therapeutic agent containing the DNA as the active ingredient.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: May 13, 2003
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Masato Yamamoto, Norio Hayashi, Hiroko Yamamoto, Naoki Tohdoh